A new study has found that patients taking GLP-1 weight loss medications in real-world settings lost less weight compared to those in clinical trials. Researchers attributed this difference to patients stopping their medication too early or taking lower doses.
According to the study, participants who stuck to their treatment and adopted a healthy lifestyle saw more significant weight loss results. However, even smaller amounts of weight loss can still lead to meaningful cardiovascular and metabolic health benefits.
The study analyzed data from nearly 7,900 GLP-1 users in Ohio and Florida who were overweight or obese but did not have type 2 diabetes. The average weight reduction after one year was 7.7% for semaglutide and 12.4% for tirzepatide, which is lower than the clinical trial results.
Experts attributed this discrepancy to various factors such as participants being healthier in trials, ideal medical settings, and struggling with side effects or accessing higher doses. However, even small amounts of weight loss can still be significant, as seen in studies showing that 5% body weight reduction can resolve health conditions like diabetes.
To increase the chances of seeing greater weight loss and metabolic benefits, experts recommend going up on the dose if possible, maintaining a healthy diet and exercise routine, and working with a multidisciplinary team to access the medication and provide necessary lifestyle changes.
Source: https://www.health.com/glp-1-drugs-real-world-weight-loss-11752679